News & Publications

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

  • 13

    Mar

    19

  • KemPharm Provides Update on APADAZ® Formulary Adoption

  • 05

    Mar

    19

  • KemPharm to Present at Upcoming Investor Conferences

  • 28

    Feb

    19

  • KemPharm Reports Q4 and FY 2018 Results

  • 21

    Feb

    19

  • KemPharm to Report Fourth Quarter and Year End 2018 Results

  • 29

    Jan

    19

  • KemPharm Announces Enhancements to U.S. and Global Intellectual Property Estate

  • 18

    Jan

    19

  • KemPharm Presenting Four Scientific Posters at APSARD’s 2019 Annual Meeting

  • 07

    Jan

    19

  • KemPharm Announces FDA Approval of sNDA for Two Additional Strengths of APADAZ® (4.08 mg benzhydrocodone/325 mg APAP and 8.16 mg benzhydrocodone/325 mg APAP)

  • 19

    Dec

    18

  • KemPharm Provides Corporate Update on Partnering Process for ADHD Prodrug Portfolio

  • 12

    Dec

    18

  • KemPharm Presents Poster at ACNP’s 57th Annual Meeting Highlighting the Intravenous Abuse Potential of Serdexmethylphenidate (SDX)

  • 11

    Dec

    18

  • KemPharm Webcast on VirtualInvestorConferences.com Now Available for On-Demand Viewing

  • 03

    Dec

    18

  • KemPharm to Webcast Live at VirtualInvestorConferences.com on December 6th

  • 13

    Nov

    18

  • KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant Use Disorder